Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Cost Plus Drugs vs YourHealthRx

Cost Plus Drugs
Graded #371

Lower grade

vs+10.900000000000006
YourHealthRx
Graded #131

Higher grade

The verdict

YourHealthRx takes it — 69.4/100 to 58.5/100.

YourHealthRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. YourHealthRx is a scientist-founded peptide and GLP-1 telehealth platform available in all 50 states and DC via a multi-state (IMLC) clinician network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueYourHealthRx +7
45
52
Dose & formulationYourHealthRx +10
65
75
Clinical oversightYourHealthRx +20
67
87
Labs & monitoringYourHealthRx +16
51
67
FulfillmentYourHealthRx +21
73
94
Contract termsCost Plus Drugs +22
55
33
Cost Plus Drugs · left barYourHealthRx · right bar

The numbers

MetricCost Plus DrugsYourHealthRx
WeighScore58.5/10069.4/100
GradeCC
Scorecard rank#371#131
Semaglutide$279/mo (brand Ozempic)$170/mo (compounded)
TirzepatideNot disclosed$210/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Cost Plus Drugs

Graded #371 · C

Strengths

  • Transparent pricing: wholesale cost + 15% markup + $5 pharmacy fee, the same for everyone
  • Around $279/mo for branded Ozempic — well below typical retail list prices
  • Mark Cuban's PBM-disrupting pharmacy, praised by Forbes Health, Wired, and KFF Health News
  • Ships to all 50 states; genuine FDA-approved Novo Nordisk Ozempic, not compounded
  • Partnered with 9amHealth so you can get prescribed and fill at Cost Plus pricing

Where it loses points

  • Fulfillment only — no telehealth intake; you need a prescription from an outside clinician
  • Ozempic is FDA-indicated for type 2 diabetes, not weight management — weight-loss use is off-label
  • Wegovy availability has been spotty — check current stock before assuming it ships
  • No compounded semaglutide or tirzepatide — brand only
  • No clinical follow-up — side-effect monitoring falls to your prescribing clinician
YourHealthRx

Graded #131 · C

Strengths

  • Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
  • Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
  • Flat subscription price that doesn't change as your dose increases (no titration penalty)
  • Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
  • Transparent, education-first positioning with published medical disclaimer, privacy, and terms

Where it loses points

  • Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
  • Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
  • Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
  • No LegitScript certification displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard